ArticleArchives of toxicology2026
Cardiovascular toxicity of ethyl maltol exposure: a comprehensive investigation from virtual screening to experimental validation.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ethyl maltol is a ubiquitous synthetic flavor enhancer. Despite its widespread use in foods, beverages, and electronic cigarettes, and its potential for environmental dispersion, its long-term cardiovascular safety remains unevaluated. Here, we employed an integrative strategy commencing with network toxicology and machine learning to identify pivotal molecular targets. The interaction between ethyl maltol and the key target was scrutinized via molecular docking and dynamics simulations. Cardiovascular toxicity was subsequently validated through in vivo and in vitro experiments, incorporating transcriptomic and single-cell RNA sequencing analyses. HMOX1 was identified as the central target. Molecular simulations confirmed stable binding between ethyl maltol and HMOX1. In mice, ethyl maltol exposure (5, 10, 20 mg/kg) induced anemia, platelet activation, reduced hindlimb perfusion, and impaired endothelium-dependent vasodilation, concomitant with upregulated vascular adhesion molecules. In human endothelial cells, ethyl maltol (10, 20, 40 μM) suppressed cell viability and triggered HMOX1 expression, NLRP3 inflammasome activation, and NF-κB signaling. Mechanistically, ethyl maltol appears to subvert the typically protective HMOX1 response into a driver of chronic vascular inflammation and adhesion. This study unveils a previously unrecognized cardiovascular risk associated with ethyl maltol, mediated through HMOX1-driven inflammatory dysregulation. It establishes a translatable paradigm for the safety assessment of prevalent food additives and environmental contaminants.
Indexed as
Identifiers
42047701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.